ArticleFrontiers in immunology2026
Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the widespread use of novel therapeutic agents, an increasing number of drugs have been confirmed to be associated with interstitial lung disease (ILD). However, real-world evidence regarding ILD reporting signals in patients with head and neck squamous cell carcinoma (HNSCC) remains limited. Methods: We performed a signal mining study using data from the FDA Adverse Event Reporting System (FAERS) database from Q1 2004 to Q1 2025. Eligible adverse event reports related to ILD in HNSCC patients were included. Disproportionality analysis was performed using the combination of reporting odds ratio (ROR) and information component (IC). Time to onset (TTO) was analyzed using descriptive statistics and Weibull distribution modeling. Results: A total of 513 patients with ILD related to HNSCC treatment in the FAERS database were included. The median age was 68.00 years (IQR 60.00-75.00), the median weight was 56.00kg (IQR 47.80-68.00), and a total of 42 drugs were involved. Based on ROR and IC, three drugs showed definite positive ILD signals: cetuximab [ROR = 1.46 (95%CI: 1.22-1.74), IC = 0.36 (95%CI: 0.12-0.60)], nivolumab [ROR = 1.67 (95%CI: 1.35-2.06), IC = 0.61 (95%CI: 0.30-0.90)], and pembrolizumab [ROR = 2.39 (95%CI: 1.93-2.96), IC = 1.06 (95%CI: 0.74-1.35)]. In addition, etoposide showed a positive ROR [ROR = 4.51 (95%CI: 1.41-14.43)] but a negative IC [IC = 2.11 (95%CI: -0.26-2.72)]. Drug class analysis revealed that anti-EGFR monoclonal antibodies [ROR = 1.45 (95%CI: 1.21-1.72), IC = 0.35 (95%CI: 0.11-0.59)] and PD-1/PD-L1 inhibitors [ROR = 2.14 (95%CI: 1.80-2.54), IC = 0.72 (95%CI: 0.49-0.95)] were classes with positive safety signals for ILD. The median TTO was 32.00 days (IQR 14.00-73.50), α=61.70 (95%CI 52.98-71.85), β=0.83 (95%CI 0.76-0.90), and ILD was mainly characterized by early onset. Conclusion: ILD reports associated with HNSCC treatment were mainly concentrated among anti-EGFR monoclonal antibodies and PD-1/PD-L1 inhibitors, with the early treatment stage representing a critical window that warrants strengthened monitoring for ILD in clinical practice. Given spontaneous reporting data, causality cannot be confirmed and further verification is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.